Vivesto AB (LON:0N4A)

Market Cap	7.41M -22.2%
Revenue (ttm)	n/a
Net Income	-2.60M
EPS	-0.43
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	177,272
Open	0.0834
Previous Close	0.0826
Day's Range	0.0834 - 0.0834
52-Week Range	0.0834 - 23.6000
Beta	0.05
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 6, 2026

About Vivesto AB

Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1988
• Employees: 4
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0N4A

Financial Performance

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 26, 2026

Data Sources Report a data error